

## COUNTRY GENERAL INFORMATION (WHO, 2015)

Total population:	13,908,129
Gender F/M (%):	50.3 / 49.7
Population, age group <15 / ≥15 years (%):	47 / 53
Life expectancy at birth (F/M, years) (2015):	57 / 54
GDP (PPP int \$):	1,399
Income status:	Low
Number of 2 <sup>nd</sup> sub-national administrative level divisions, name:	90, District

## EPIDEMIOLOGY


	VL	CL	PKDL	MCL
Endemicity status:	Endemic	Non endemic	Non endemic	Non endemic
Number of new cases (incidence):	1,165	N/A	N/A	N/A
Number of relapse <sup>1</sup> cases:	1	N/A	N/A	N/A
<b>Total number of cases:</b>	<b>1,166</b>	<b>N/A</b>	<b>N/A</b>	<b>N/A</b>
Imported cases (#, %):	No data	No data	No data	No data
Gender distribution (% F):	39	N/A	N/A	N/A
Age group distribution (% < 5/5-14/>14):	(63/30/6)	N/A	N/A	N/A
Incidence rate (cases/10,000 population in endemic areas):	4.98	N/A	N/A	N/A
Number of endemic 2 <sup>nd</sup> sub-national administrative level divisions:	14	N/A	N/A	N/A
Population at risk <sup>2</sup> (% # at risk/total population):	17 % 2,337,787/ 13,908,129	N/A	N/A	N/A
Was there any outbreak?	Not available	N/A	N/A	N/A
Number of new <sup>3</sup> foci:	Not available	N/A	N/A	N/A

N/A = Not applicable; <sup>1</sup> Relapse in this country is defined as: "A patient who has completed the full treatment course, or at least 15 days with appropriate amount of antimonials as single therapy more than one month ago and then returns with proven kala-azar. Relapses are diagnosed parasitologically"; <sup>2</sup> Defined as: "Number of people living in 2<sup>nd</sup> sub-national administrative level endemic areas"; <sup>3</sup> Defined as: "In this reporting period, an area at the 2<sup>nd</sup> sub-national administrative level reporting cases for the first time ever."


## Monthly distribution of new VL cases (January-December)

2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	149	100	75	50	130	99	102	125	110	61	92	72


VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis



## Incidence rate/10,000 (at the national level) and number of new VL cases from 1998 to 2015



## Disease distribution of new VL cases at district level per 10,000 population (2015)



\* All the cases reported in Bosaso hospital were considered living in Bosaso district

www.who.int/leishmaniasis/Map-VL-Somalia-2015.png

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.  
Map production: WHO/HTM/NTD/IDM

## CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	Not available
Type of surveillance:	Other
Is there a vector control programme?	No
Type of insecticide used for Indoor residual Spraying (IRS):	N/A
Year latest national guidelines:	2012
Is leishmaniasis notifiable (mandatory report)?	No
Is there a reservoir host control programme?	No
Number of leishmaniasis health facilities:	3

## DIAGNOSIS

	VL	CL	PKDL	MCL
Number of people screened actively for:	0	No data	N/A	N/A
Number of people screened passively for:	1,163	No data	N/A	N/A
Cases diagnosed by RDT* (% , # RDT+/ total VL cases):	86% (1,006/1,166)	N/A	N/A	N/A
Proportion of positive RDT* (% , # RDT+/total RDT):	87% (1,006/1,163)	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (% , # slides + / total cases):	0%, (0/1,166)	N/A	N/A	N/A
Proportion of positive slides* (% , # slides + / total slides):	N/A	N/A	N/A	N/A
Cases diagnosed clinically* (% , # clinical cases/ total cases):	13%, (157/1,166)	N/A	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:	N/A	N/A	N/A	N/A
Proportion of CL cases with 4 or more lesions*:	N/A	N/A	N/A	N/A
Percentage of cases with HIV coinfection*:	No data	N/A	N/A	N/A

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis  
N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus

## TREATMENT AND MEDICINES

- ▶ Is treatment provided for free in the public sector? **Yes**
- ▶ Antileishmanial medicines included in the National Medicine List: **Sodium stibogluconate (SSG)**

### TREATMENT OUTCOME

	VL
Proportion of cases treated*(%, # treated cases/ total cases):	88% (1,031/1,166)
Initial cure rate*(%, # cases initially cured /total cases):	58% (657/1,166)
Failure rate <sup>4</sup> *(%, # patients with treatment failure /total cases):	0% (0/1,166)
Case fatality rate*(%, # patients who died/ total cases):	1% (9/1,166)

<sup>4</sup> Failure in this country is defined as: "a patient who does not respond favourably during the first 2 weeks of treatment with SSG."

\* These indicators only apply to new cases